Statute Details
- Title: Medicines (Medical Advertisements) Regulations
- Act Code: MA1975-RG2
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Medicines Act (Chapter 176), Sections 52 and 74
- Current Status: Current version as at 27 Mar 2026
- Key Commencement / Versioning Notes: The Regulations have undergone multiple amendments (e.g., S 548/2016 effective 1 Nov 2016; S 462/2022 effective 1 Jul 2022; S 493/2024 effective 1 Jul 2024). Practitioners should confirm the applicable version for the relevant period.
- Key Provisions (as reflected in the extract): Regulation 2 (definitions); Regulation 3 (permit requirement); Regulation 4 (application form); Regulation 5 (validity); Regulation 6 (terms and conditions); Regulation 7 (refusal/suspension/revocation and appeal); Regulation 8 (duty of printer/publisher); Regulation 10–11 (exceptions); Regulation 12 (permit number display); Regulation 13 (alterations); Regulation 13A (transfer of permit); Regulation 14 (fees); Regulation 15 (penalty)
- Schedule: Fees (amounts specified in the Schedule)
What Is This Legislation About?
The Medicines (Medical Advertisements) Regulations establish a licensing and compliance framework for advertising medicinal products in Singapore. In plain terms, they require most “medical advertisements” and “sales promotions” to be approved by the licensing authority before they are issued or conducted. The Regulations aim to ensure that promotional content for medicines is controlled, traceable, and subject to regulatory oversight.
The scope is not limited to pharmaceutical manufacturers. It applies broadly to “any person” who issues or publishes medical advertisements, including those who commission, print, publish, or run promotional campaigns. This means that advertising agencies, publishers, printers, and marketing teams can all be implicated if they participate in publishing content without the required permit.
While the Regulations are advertisement-focused, they operate as a gatekeeping mechanism. They do not merely regulate the content of advertisements; they regulate the process—requiring permits, setting validity periods, imposing conditions, and requiring permit numbers to be displayed. The Regulations also provide limited exceptions for certain types of communications (for example, trade or reference advertisements) and for communications that are not accessible to the general public.
What Are the Key Provisions?
1. Definitions and what counts as a “medical advertisement” and “sales promotion” (Regulation 2)
The Regulations define “medical advertisement” as any advertisement of a medicinal product, but exclude certain advertisements referenced in the Medicines Act (section 51(1)(a) or (b) or (2)). This definitional structure matters in practice: parties must first determine whether their proposed communication falls within the regulated category. If it does, the permit regime is triggered.
“Sales promotion” is defined broadly to include sales campaigns (including door-to-door sales and price discounts), exhibitions, competitions, and other activities intended to introduce, publicise, raise awareness, or increase visibility of the medicinal product. This is significant because a “permit” is not only required for traditional ads; it is also required for promotional activities that may not look like advertising in the ordinary sense.
2. Core permit requirement (Regulation 3)
Regulation 3 is the central rule: except as provided in the Regulations, no person shall (a) issue or cause to be issued any medical advertisement, or (b) conduct any sales promotion, without first obtaining a permit from the licensing authority. This is a strict procedural requirement. In enforcement terms, the prosecution does not need to prove that the advertisement was misleading; the offence is framed around contravention or failure to comply with the permit requirement.
3. Applications, validity, and conditions (Regulations 4–6)
Applications for a permit (or renewal) must be made in the form required by the licensing authority (Regulation 4). Permits are valid for one year from the date granted unless sooner revoked (Regulation 5). Practitioners should therefore treat permits as time-limited compliance instruments and build renewal timelines into marketing and regulatory planning.
Regulation 6 provides that a permit may be granted subject to such terms and conditions as the licensing authority thinks fit to impose. This gives the licensing authority discretion to tailor requirements to the advertisement or promotional campaign. In practice, counsel should assume that permit conditions may include content restrictions, required disclaimers, approval of artwork/copy, or other compliance steps. Non-compliance with permit conditions can create regulatory risk even if a permit exists.
4. Refusal, suspension, revocation, and appeal (Regulation 7)
Under Regulation 7, the licensing authority may refuse to grant a permit, or suspend or revoke an existing permit, without assigning any reason. This is a notable feature: applicants may not receive a detailed explanation, which can complicate internal remediation and resubmission strategy.
Any person aggrieved may appeal to the Minister, and the Minister’s decision is final. For practitioners, this means that administrative remedies are limited and time-sensitive. Where a permit is refused or revoked, counsel should quickly assess whether an appeal is warranted and whether the appeal should be supported by revised materials, additional evidence, or compliance changes.
5. Duties of printers and publishers (Regulation 8)
Regulation 8 imposes a compliance duty on the supply chain. No person shall print or publish (or cause to be printed or published) any medical advertisement that is not a sales promotion unless they have first ascertained that a permit has been granted for that advertisement. This provision is particularly important for publishers, printers, and media platforms: they cannot simply rely on a client’s assurance that approval exists. They must take steps to verify the permit status.
6. Exceptions for certain audiences and communications (Regulations 10–11)
Regulation 10 provides an exception where the medical advertisement is directed exclusively at persons who may lawfully sell or supply medicinal products in the course of their trade, business, or profession, and is not accessible to the general public. This is a “targeting and accessibility” test. Practitioners should consider how “directed exclusively” and “not accessible to the general public” will be evidenced—e.g., controlled distribution lists, restricted access portals, or mechanisms preventing public viewing.
Regulation 11 further excludes certain categories: (a) reference advertisements and trade advertisements, and (b) medical advertisements issued or published by public authorities or persons authorised by the Minister. The Regulations define “reference advertisement” and “trade advertisement” with specific characteristics. For example, a reference advertisement is brief and may include contraindications or warnings, and appears without charge in a publication mainly consisting of such advertisements sent to practitioners or pharmacists by a person not involved in the sale of the medicinal product as a manufacturer, supplier, retailer, importer or exporter. A trade advertisement is typically a catalogue or price list for wholesale supply and must not contain recommendations relating to use other than as part of the medicinal product name or therapeutic classification heading/sub-heading.
7. Permit number display (Regulation 12)
Any person who issues or publishes a medical advertisement (including conducting a sales promotion) must ensure that the permit number is displayed on, or on material accompanying, the advertisement in accordance with terms and conditions specified in the permit. This requirement supports traceability and helps regulators and consumers identify the approved promotional material. Practically, counsel should ensure that permit numbers are correctly formatted and placed as required by the permit conditions.
8. Alterations and amendments (Regulation 13)
A person must not alter or amend the contents of a medical advertisement for which a permit has been granted unless (a) an application is made in the form required to amend the permit to reflect the alteration, and (b) the application is approved by the licensing authority. This is a key compliance point for marketing teams: even minor copy changes, updated claims, revised visuals, or new disclaimers can require an amendment approval. “Version control” becomes essential.
9. Transfer of permits (Regulation 13A)
A permit cannot be transferred unless an application is made in the required form and approved by the licensing authority. This matters in corporate transactions, outsourcing arrangements, or changes in brand ownership. Practitioners should not assume that a permit automatically follows the business; regulatory approval is required for transfer.
10. Fees and no refunds (Regulation 14 and the Schedule)
Fees are payable for applications for permits, permits/renewals, amendments to permits, and applications to transfer one or more permits. The specific amounts are set out in the Schedule. Regulation 14(2) states that no refund shall be made in respect of any fee paid. Counsel should therefore advise clients on cost planning and the risk of non-refundable fees where applications are withdrawn or unsuccessful.
11. Penalty for contravention (Regulation 15)
Regulation 15 provides that any person who contravenes or fails to comply with Regulations 3, 8, 12 or 13 commits an offence. On conviction, liability may include a fine not exceeding $5,000, imprisonment for up to 12 months, or both. This penalty provision underscores the seriousness of procedural compliance: the offence is tied to the permit requirement, printer/publisher verification duty, permit number display, and restrictions on altering permitted advertisements.
How Is This Legislation Structured?
The Regulations are structured as a set of numbered regulations supported by a Schedule. The main workflow is: (1) definitions (Regulation 2), (2) permit requirement (Regulation 3), (3) application and administrative mechanics (Regulations 4–6), (4) regulatory decisions and appeal (Regulation 7), (5) compliance duties for those who print/publish (Regulation 8), (6) exceptions (Regulations 10–11), (7) operational requirements for permit identification and content control (Regulations 12–13A), and (8) administrative costs and enforcement (Regulations 14–15). The Schedule sets out the fees payable.
Who Does This Legislation Apply To?
The Regulations apply to “any person” who issues or causes to be issued medical advertisements or conducts sales promotions without a permit, subject to the stated exceptions. This broad phrasing captures not only brand owners and manufacturers, but also advertising agencies, marketing contractors, publishers, printers, and potentially other intermediaries involved in dissemination.
Regulation 8 specifically targets printers and publishers by requiring them to ascertain that a permit has been granted before printing or publishing medical advertisements (where the advertisement is not a sales promotion). Additionally, the permit number display obligation (Regulation 12) applies to those who issue or publish advertisements and those conducting sales promotions. In practice, compliance responsibility is distributed across the promotional supply chain.
Why Is This Legislation Important?
For practitioners, the Regulations are important because they provide a clear procedural compliance regime for medicine advertising—one that can be enforced through criminal penalties. The offence provisions focus on contravention of the permit requirement and related compliance steps, meaning that companies can face liability even where the underlying promotional content might otherwise be defensible on substantive grounds.
From a commercial perspective, the one-year validity period and the requirement for permit amendments for alterations create operational constraints. Marketing teams must implement governance processes: obtaining permits before launch, tracking expiry dates, ensuring that any creative changes are submitted for approval, and maintaining accurate records of permit numbers and versions.
Finally, the exceptions for trade, reference, and controlled professional communications are nuanced. A misclassification—such as assuming a communication is “trade” when it contains recommendations beyond what is permitted, or assuming a message is not accessible to the general public when it is—can trigger the permit requirement and enforcement risk. Legal review is therefore critical when designing distribution strategies and promotional formats.
Related Legislation
- Medicines Act (Chapter 176): Authorising provisions include Sections 52 and 74; the definition of “medical advertisement” cross-refers to advertisements mentioned in Section 51(1)(a), (b) and Section 51(2).
Source Documents
This article provides an overview of the Medicines (Medical Advertisements) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.